phive2015 Shares of Mustang Bio ( NASDAQ: MBIO ) rallied for the second day in a row, with shares up 45% in afternoon trading Tuesday after closing 477% higher Monday following positive data for the company’s blood cancer drug candidate MB-106. Mustang Bio shares opened at $0.97, later hitting a high of $1.
30. The stock recently sold for $1.09 at around 1:40 p.
m. ET. On Monday, Mustang reported positive data from a Phase 1/2 trial for its CAR-T cell therapy MB-106 in the treatment of Waldenstrom macroglobulinemia, a type of non-Hodgkin lymphoma.
Mustang presented the data at the European Hematology Association 2024 Hybrid Congress. More on Mustang Bio Mustang Bio stock rockets 580% on blood cancer drug study Mustang Bio stock tumbles 27% amid news of mass layoffs Seeking Alpha’s Quant Rating on Mustang Bio Historical earnings data for Mustang Bio Financial information for Mustang Bio.
